The mRNA Cancer Vaccine Summit 2023 comes to Boston as the community is on the cusp of something truly exciting. This is the first and only forum dedicated to showcasing mRNA cancer vaccine technology advances, translational insights and critical clinical updates from the global leaders working towards effective harnessing of neoantigens and developing successful tailor-made mRNA cancer vaccines. Unite with mRNA cancer vaccine, oncology and immune-oncology leaders and stay up to date about these innovative cancer therapies. With individualized neoantigen therapies showing critical promise in the clinic, neoantigen leaders unite to exhibit a whole-day dedicated to neoantigen discovery and identification, towards optimized discovery and development of personalized cancer vaccines to differentiate and fast track your pipelines.
The ESMO Congress is the most influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. ESMO 2023 will disseminate the latest cutting-edge data, provide high-quality education and unparalleled networking opportunities for oncologists and other stakeholders from all around the world.
From 6th to 8th November 2023 leading biotech and biopharma companies and development teams will gather in Messe Munich to realise BIO-Europe 2023. The show floor will feature an elaborate curated product offering alongside immersive conference agenda. BIO-Europe 2023 will shed light on vital industry topics, including AI, pharmaceuticals, preventative medicine, big data and more.
NextGen Omics 2023 features 4 outstanding programmes, bringing together Europe’s most successful omics research experts under one roof. The series provides an excellent networking platform which consists of key discussion topics in: Next Generation Sequencing & Clinical Diagnostics, Single Cell & Spatial Analysis, Synthetic Biology in Discovery & Therapeutics and Digital PCR & Liquid Biopsies
The 6th Biologics World Nordics 2023 event will bring together biologic and biosimilar developers and manufacturers, technology providers, CMOs and CROs from the Nordics region and beyond to explore partnership and technical collaboration opportunities, discuss best R&D and biomanufacturing practises, and debate growth strategies as Nordics developed biologics enter critical clinical phase II and III development stages.
The purpose of the meeting is to exchange information among academia, industry, advocacy and federal agencies on the current status and the challenges to develop and license a CMV vaccine.
NIAID Conference Center
5601 Fisher Lane
Rockville, MD 20852
The 23rd International Pathogenic Neisseria Conference aims to bring together passionate scientists, emerging and experienced researchers and clinicians from all continents to discuss the clinical presentation, epidemiology, population genomics, vaccine research and development, host-pathogen interactions and gene regulation of these Neisseria species in order to keep abreast of the latest developments in this field. IPNC is a great opportunity for networking and forming collaborations for future work on pathogenic Neisseria species.
Join vaccines leaders, experts and distinguished scientists in Europe, delivering breakthrough research, technologies & connecting global pharma, biotech and academia for high-level discussions on the latest innovations within the vaccines discovery, therapeutics & manufacturing.
The R&D Day will feature a series of talks from Evaxion scientists and collaborators, sharing previously unreleased preclinical data highlighting the use of Evaxion’s proprietary genetic immune adjuvant (Antigen Presenting Cell targeting) technology. This technology has been shown to enhance vaccination effects for both DNA and mRNA vaccines across a range of therapeutic vaccine applications.
The event will be hosted with the possibility of physical attendance at Evaxion’s facilities in Hørsholm, Denmark and as a live webcast.
Please write to email@example.com with the following details to sign up for the physical attendance for R&D day:
Subject: R&D Day
Message: Your full name
Dr Neergaards Vej 5F,
If you are a holder of an ADR (American depositary receipt – a US issued certificate representing shares in a foreign company for trade on American stock exchange) and wish to know what applies in terms of voting or giving proxy, please refer to your depositary agreement with your broker.
Notice of general meetings will be published on the company web-site. If you are a Danish holder of shares you can also sign up for future notices at https://virk.dk/
Evaxion will be presenting a scientific presentation on our antigen presenting cell targeting technology for this year's World Vaccine Congress.
Reach out to Neil Anderson, VP and Global Head of Business Development (firstname.lastname@example.org)
Toll Free: 1-877-407-0792
Conference ID: 13720456
Toll Free: 1-877-407-0792